Intracranial and whole-body response of ceritinib in ALK inhibitor-naïve and previously ALK inhibitor-treated patients with ALK-rearranged non-small-cell lung cancer (NSCLC): updated results from the phase 1, multicentre, open-label ASCEND-1 trial

BACKGROUND: ALK-rearranged non-small-cell lung cancer (NSCLC) is sensitive to ALK tyrosine kinase inhibitors (ALKi) such as crizotinib, but resistance invariably develops, often with progression in the brain. Ceritinib is a more potent ALKi than crizotinib in vitro, crosses the blood-brain barrier i...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Dong-Wan, Mehra, Ranee, Tan, Daniel S W, Felip, Enriqueta, Chow, Laura Q M, Camidge, D Ross, Vansteenkiste, Johan, Sharma, Sunil, De Pas, Tommaso, Riely, Gregory J, Solomon, Benjamin J, Wolf, Jürgen, Thomas, Michael, Schuler, Martin, Liu, Geoffrey, Santoro, Armando, Sutradhar, Santosh, Li, Siyu, Szczudlo, Tomasz, Yovine, Alejandro, Shaw, Alice T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063047/
https://www.ncbi.nlm.nih.gov/pubmed/26973324
http://dx.doi.org/10.1016/S1470-2045(15)00614-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063047/
https://www.ncbi.nlm.nih.gov/pubmed/26973324
http://dx.doi.org/10.1016/S1470-2045(15)00614-2

Ejemplares similares